Holen Sie sich die Stockscreener-App
4.33
1.37%
-0.06
Handel nachbörslich:
4.33
Schlusskurs vom Vortag:
$4.39
Offen:
$4.52
24-Stunden-Volumen:
14.66M
Relative Volume:
0.60
Marktkapitalisierung:
$2.32B
Einnahmen:
$64.60M
Nettoeinkommen (Verlust:
$-377.75M
KGV:
-2.7935
EPS:
-1.55
Netto-Cashflow:
$-335.64M
1W Leistung:
-24.04%
1M Leistung:
-6.88%
6M Leistung:
-39.01%
1J Leistung:
-49.88%
1-Tages-Spanne:
$4.31
$4.63
1-Wochen-Bereich:
$4.11
$5.80
52-Wochen-Spanne:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Vergleichen Sie RXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.33 | 2.32B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharmaceuticals outlines focused R&D pipeline with multiple catalysts through 2026 - MSN
Recursion Pharmaceuticals files prospectus supplement By Investing.com - Investing.com India
Recursion Pharmaceuticals files prospectus supplement - Investing.com Australia
Recursion Pharmaceuticals Registers Shares for Resale - TipRanks
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week - The Motley Fool
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week - Barchart.com
(RXRX) Long Term Investment Analysis - news.stocktradersdaily.com
Retail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial Data - MSN
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates - MSN
Earnings Release: Here's Why Analysts Cut Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target To US$7.43 - Yahoo Finance
Why Recursion Pharmaceuticals Stock Is Plummeting Today - The Globe and Mail
Recursion axes drug programmes to streamline pipeline - Yahoo Finance
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Recursion to Participate in Upcoming Investor Conferences - The Manila Times
BofA Adjusts Price Target for RXRX Following Pipeline Changes | RXRX Stock News - GuruFocus
Recursion Pharmaceuticals Inc (RXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships ... By GuruFocus - Investing.com Canada
Recursion Pharmaceuticals (RXRX) Advances Drug Programs with Str - GuruFocus
Recursion Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Recursion Pharmaceuticals: Q1 Earnings Snapshot - MySA
Recursion Pharmaceuticals’ Earnings Call: Balancing Success and Challenges - TipRanks
Recursion Pharmaceuticals Q1 2025 Earnings: EPS Beats Estimates at -$0.50, Revenue Misses at $15 Million - GuruFocus
Recursion Pharmaceuticals (RXRX) Reports Q1 Earnings: EPS Surpas - GuruFocus
Recursion (RXRX) Reports Q1 Revenue Shortfall, Focuses on Stream - GuruFocus
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday - Mitrade
Earnings call transcript: Recursion Pharmaceuticals Q1 2025 results miss estimates By Investing.com - Investing.com South Africa
Earnings call transcript: Recursion Pharmaceuticals Q1 2025 results miss estimates - Investing.com Nigeria
Recursion Pharmaceuticals (RXRX) Advances Drug Programs with Strategic Focus - GuruFocus
Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial Results - Yahoo Finance
Recursion Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
AI specialist Recursion trims pipeline in latest shakeup - BioPharma Dive
Why Recursion Pharmaceuticals Stock Was Getting Mashed On Monday - Barchart.com
Recursion Deprioritizes 3 Clinical Programs Following Data-Driven Review, Stock Down - Nasdaq
Document - SEC.gov
Recursion Pharmaceuticals earnings missed by $0.01, revenue fell short of estimates - Investing.com Canada
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Recursion Pharmaceuticals Q1 Loss Widens, Revenue Increases - marketscreener.com
Recursion Pharmaceuticals Reports Q1 Results and Strategy Update - TipRanks
RECURSION PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus - Genetic Engineering and Biotechnology News
Recursion Pharmaceuticals Reports Promising Early Results for Familial Adenomatous Polyposis Drug Trial - marketscreener.com
Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings (NASDAQ:RXRX) - Seeking Alpha
Recursion (RXRX) Reports Promising Results for FAP Treatment - GuruFocus
Preliminary Phase 1b/2 Data for REC-4881 in Familial - GlobeNewswire
Recursion's REC-4881 Shows Promising Results in TUPELO Trial | R - GuruFocus
Recursion's REC-4881 Shows Promising Results in TUPELO Trial | RXRX Stock News - GuruFocus
Recursion Pharmaceuticals (RXRX) Set to Release Q1 Earnings - GuruFocus
Did Jim Cramer Nail All These 9 Stock Predictions? - Insider Monkey
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing - MSN
Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)? - Insider Monkey
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):